MA
Maze Therapeutics, Inc.
MAZE · NASDAQ
$22.52 -3.84% (-$0.90)
1M -23.92%
Market Cap $1.25B
P/E Ratio -
Div. Yield -
ROE 34.94%
Piotroski F-Score Weak
3/9Valuation
36 /100
Fair P/B 2.75x
P/S 62.32x
P/FFO N/A
Growth
100 /100
Growing Book val. growth 51.82%
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak Net margin 667.95%
Op. margin 728.06%
FCF margin 534.20%
Quality
0 /100
Poor ROE 34.94%
ROA 25.13%
Asset turnover 0.04x
Debt
69 /100
Low Current ratio 18.31x
Int. coverage -73.34x
Debt/Equity 0.13x
Stability
1 /100
Unstable EPS volatility 2,355.06%
Profitable years 0
Beta 2.16x
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o MAZE
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jason Coloma
Employees
141
Headquarters
South San Francisco
Prihajajoči dogodki
05 NOV.
Earnings
Upcoming earnings report